Aberdeen scientists to explore African seas for drug discoveries
Research could lead to new treatments for cancer and MRSA
A team will travel to Ghana next month to search the waters for unique marine organisms that could be used to develop new medicines.
The scientists hope to find previously undiscovered species of corals, sponges and sea squirts. They will examine these organisms for new molecules, bacteria and fungi, which could be used in the creation of new treatments for diseases prevalent in Africa – including tuberculosis and parasitic diseases such as malaria.
Professor Marcel Jaspars, director of the Marine Biodiscovery Centre, said: ‘Drug discovery work in West Africa has historically focused on land, investigating how molecules in plants can be used in the development of new medicines.
‘Our project marks the first time waters off the coast of West Africa have been explored to assess the diversity of marine organisms available in this area, and the potential they could harbour in the treatment of a number of diseases.’
Jaspars said the team would collect samples at low tide around the Gulf of Guinea and Guinea Basin, where they believe they will find new species.
The Aberdeen scientists will work with the University of Ghana during the trip, which marks the beginning of a three-year collaborative project between the two institutions.
The £1.6m Marine Biodiscovery Centre – which brings together chemists and biologists to work on the development of new pharmaceuticals from organisms from the depths of the world’s oceans – opened in June. It is one of only three in Europe dedicated to the exploration of the natural resources from our seas.
The project is funded by the Leverhulme Trust and co-ordinated by the Royal Society.
You may also like
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
Read moreA new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Trending Articles
You may also like
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Research & Development
Reacta Healthcare announces expansion into Asia-Pacific and appoints Professor Gary Wing-Kin Wong to advisory board
Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint
Research & Development
BioDuro and CTI Technology partner to push forward preclinical drug development
The duo will combine their manufacturing experience and analytical capabilities to build an integrated platform spanning all the way from drug discovery to IND submission to accelerate the drug development path for clients
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections